摘要
在临床研究中观察了伊沙匹隆、Larotaxel及新的联合化疗方案治疗耐蒽环和耐紫杉醇类药物的复发转移乳腺癌；类固醇硫酸酯酶抑制物三环氨基硫酸酯及依西美坦联合塞来昔布治疗绝经后耐三苯氧胺的晚期乳腺癌；拉帕替尼、培美曲塞及其联合方案靶向治疗耐曲妥珠HER-2阳性转移乳腺癌。结果显示了良好的疗效及安全性。部分研究结果值得进一步观察。
In the current clinical trials, observed treatment on recrudescent and metastatic breast canc- er which can be anthracycline-resistant and taxane-resistant with Ixabepilone ,Larotaxel and their combination; and treating climacteric -positive and tamoxifen-resistant advanced breast cancer with steroid sulfatase inhibitor STX64 or combination of exemestane and celecoxib; Treating chemotherapy-refractory HER2-positive metastatic breast cancer with lapatinib and pemetrexed as well as their combination. Results have demonstrated superior efficacy and safety, and some of which are worthy of further observation.
出处
《国际肿瘤学杂志》
CAS
2009年第2期133-135,共3页
Journal of International Oncology
